GCG and obesity disorder: Furthermore, anti-obesity pharmacotherapies—including GLP-1 RAs—have shown promise not only in facilitating substantial and sustained weight loss but also in reducing systemic inflammation and improving comorbid metabolic conditions, such as insulin resistance and hypertension, which are prevalent in OSA populations (111, 120).